A detailed history of Exodus Point Capital Management, LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 91,636 shares of BPMC stock, worth $8.42 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
91,636
Previous 21,041 335.51%
Holding current value
$8.42 Million
Previous $2 Million 394.84%
% of portfolio
0.07%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$85.18 - $108.78 $6.01 Million - $7.68 Million
70,595 Added 335.51%
91,636 $9.88 Million
Q1 2024

May 14, 2024

SELL
$73.17 - $99.79 $14.1 Million - $19.2 Million
-192,368 Reduced 90.14%
21,041 $2 Million
Q3 2023

Nov 09, 2023

BUY
$46.9 - $66.0 $9.52 Million - $13.4 Million
202,980 Added 1946.3%
213,409 $10.7 Million
Q2 2023

Aug 10, 2023

SELL
$42.2 - $66.37 $13.4 Million - $21.1 Million
-317,430 Reduced 96.82%
10,429 $659,000
Q1 2023

May 11, 2023

BUY
$37.97 - $50.0 $6.47 Million - $8.52 Million
170,492 Added 108.34%
327,859 $14.8 Million
Q4 2022

Feb 13, 2023

BUY
$41.06 - $66.48 $6.46 Million - $10.5 Million
157,367 New
157,367 $6.89 Million
Q3 2022

Nov 10, 2022

SELL
$49.93 - $77.7 $848,210 - $1.32 Million
-16,988 Closed
0 $0
Q2 2022

Aug 19, 2022

BUY
$45.23 - $70.15 $768,367 - $1.19 Million
16,988 New
16,988 $858,000
Q1 2021

May 17, 2021

SELL
$90.71 - $108.28 $2.37 Million - $2.83 Million
-26,181 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$92.08 - $124.48 $1.67 Million - $2.25 Million
18,107 Added 224.26%
26,181 $2.94 Million
Q3 2020

Nov 16, 2020

BUY
$66.45 - $92.7 $287,994 - $401,761
4,334 Added 115.88%
8,074 $748,000
Q2 2020

Aug 14, 2020

BUY
$57.09 - $79.27 $213,516 - $296,469
3,740 New
3,740 $292,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.49B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.